profit from every $100 of sales.
$0$100
NeuroPace
$7.56-37.10% today
-41.0% in 1 year
1-year low $7.561-year high $19.29
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What NeuroPace sold, what it kept, and what it did with the cash.
Sales went from $45.5 million in 2022 to $100.0 million in 2025, with -$21.5 million of profit last year.
SalesProfit
NeuroPace vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| NeuroPace | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads NeuroPace's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 46 | 65 | 80 | 100 | |
| 32 | 48 | 59 | 77 | |
| -41 | -27 | -22 | -16 | |
| -37 | -23 | -17 | -12 | |
| -47 | -33 | -27 | -21 | |
| -1.91 | -1.27 | -0.93 | -0.66 | |
| 71.4% | 73.6% | 73.9% | 77.2% | |
| -89.6% | -41.5% | -27.1% | -16.3% | |
| -103.4% | -50.4% | -34.0% | -21.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 114 | 108 | 95 | 106 |
| Cash | 7 | 18 | 13 | 22 |
| Total debt | 70 | 72 | 73 | 71 |
| Total liabilities | 79 | 87 | 87 | 87 |
| 35 | 21 | 8 | 19 | |
| 25 | 26 | 29 | 33 | |
| -29.9% | -20.7% | -17.8% | -12.3% | |
| -135.4% | -159.6% | -338.7% | -112.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -37 | -20 | -18 | -11 | |
| 1 | 0 | 0 | 0 | |
| -37 | -20 | -18 | -11 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 50 | |
| 8 | 10 | 10 | 11 |
Valuation
- –
- –
- –
- 39.5×
- 2.6×
- –
- –
- -4.4%
- -8.3%
- 0.0%
Profitability
- 77.2%
- -16.3%
- -21.5%
- -14.9%
- -19.7%
- -33.4%
- -120.7%
- -21.8%
- -20.3%
- 27.8%
Growth
- +30.0%
- –
- +37.9%
- –
- +18.5%
Financial health
- –
- 4.87
- 71.2%
- -2.7×
- 5.38
- 4.35
- 1.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 952
Bottom 13%of 884
Top 18%of 886
Bottom 20%of 987
What analysts expect
- Average price target
- $19.00
- Range
- $16.00 – $22.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.13 | -0.19 | +31.6% |
| Mar 3, 2026 | -0.08 | -0.14 | +42.9% |
| Nov 4, 2025 | -0.11 | -0.20 | +45.0% |
| Aug 12, 2025 | -0.26 | -0.24 | −8.3% |
| May 13, 2025 | -0.21 | -0.26 | +19.2% |
| Mar 4, 2025 | -0.18 | -0.25 | +28.0% |
| Nov 12, 2024 | -0.19 | -0.26 | +26.9% |
| Aug 13, 2024 | -0.26 | -0.29 | +10.3% |
News
NeuroPace expects ~15% RNS growth in 2027 as it revises 2026 revenue guidance to $91M-$92MSeeking Alpha · Nov 13, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
20No pass
Philip Fisher
42No pass
Peter Lynch
43No pass
Joel Greenblatt
0No pass
Charlie Munger
22No pass
Terry Smith
32No pass
Questions about NeuroPace
Is NeuroPace a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the NeuroPace AI analysis
What does NeuroPace do?
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. It is in Medical - Devices.
Does NeuroPace pay a dividend?
No. NeuroPace does not pay a dividend at the moment; in 2025 it returned $49.5 million to shareholders by buying back its own shares.
Is NeuroPace stock halal?
Yes. NeuroPace passes our halal screen: its business is permitted and its debt is 27% of its market value, under the 30% limit. How we check
How has NeuroPace stock done over the past year?
Down 41.0% over the past twelve months, to $7.56. It traded between $7.56 and $19.29 and is 60.8% below its high.
Who are NeuroPace's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with NeuroPace's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.